--- title: 联系Profil的Dr. Susanne Famulla description: 与Profil的Dr. Susanne Famulla取得联系。 --- [![Profil Logo](https://info.profil.com/hs-fs/hub/481167/file-2427498648.png?width=500&name=file-2427498648.png "Profil Logo")](https://www.profil.com?hsLang=zh) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) ![Contact our experts header](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_About_Profil.jpg?width=1077&name=Header_1077x260px_About_Profil.jpg "Contact our experts header") # 认识和联系Profil的专家   |  ![Susanne Famulla_Hex_](https://info.profil.com/hs-fs/hubfs/Susanne%20Famulla_Hex_.png?width=155&name=Susanne%20Famulla_Hex_.png) | ### Susanne Famulla 博士 科学研究顾问 Susanne是您在以下领域的联系伙伴: - 胰岛素药效学和药代动力学 - 1型糖尿病的非胰岛素辅助疗法 - 胰岛素引起的脂肪增生 | | --- | --- | ### 简介 Susanne于2012年10月加入Profil的项目开发团队，担任科学研究顾问。她是一名化学家，具有基础科学的学术背景，专注于分子生物化学。在杜塞尔多夫德国糖尿病中心的博士学位论文中，她研究了脂肪组织中脂肪因子的分泌和炎症，以及脂肪组织在肥胖引起的糖尿病中的潜在作用。 在Profil，她从事临床试验的设计和宣传，重点研究1型糖尿病患者的新型胰岛素和非胰岛素辅助疗法。她是新型胰岛素制剂药效学和药代动力学方面的专家，以及用于优化1型糖尿病治疗方法的专家。 ### 发表物 以下是Susanne的近期发表物: - Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH. [ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).](https://pubmed.ncbi.nlm.nih.gov/33336850) DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print.  - Heise T, Norskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. [Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes.](https://www.ncbi.nlm.nih.gov/pubmed/28295934) DIABETES OBES METAB 2017 Mar 14. doi: 10.1111/dom.12938 (Epub ahead of print) - Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kaltheuner M, Kaltheuner L, Heinemann L, Heise T, Hirsch L. [Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action, and impaired postprandial glucose control](http://www.ncbi.nlm.nih.gov/pubmed/27411698). DIABETES CARE 39: 1486-1492, 2016 - Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). DIABETES OBES METAB 2015. doi: 10.1111/dom.12494 浏览Profil的[发表物列表](https://www.profil.com/knowledge-center/publications?hsLang=zh)以查看我们的其他发表物。   主要成就及工作经验 | Since October 2012 | Scientific Study Advisor, Profil Neuss | | --- | --- | | 06/2012 - 09/2012 | Quality Control Manager, Profil Neuss | | 2007 - 2012 | PhD Programme at the German Diabetes Center, Düsseldorf | | 2002 - 2017 | Studies of Chemistry at the Heinrich-Heine University, Düsseldorf | ### 联系Susanne Famulla 博士 ![blank.jpg](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_References.png?width=49&height=49&name=Icon_References.png) #### References We have published with the following sponsors: ![Referenzen](https://info.profil.com/hubfs/BLUE_MOON/content-bilder/Referenzen.gif "Referenzen") [View more](https://info.profil.com/knowledge-center/references?hsLang=zh) ![blank.jpg](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Certificates.png?width=44&height=49&name=Icon_Certificates.png) #### Certificates | ![13485_Zertifikatssiegel_black_A3](https://info.profil.com/hubfs/BLUE_MOON/piktos/ISO_134852016_certificate_blue.png) ISO 13485:2016 ![27001_Zertifikatssiegel](https://info.profil.com/hubfs/BLUE_MOON/piktos/ISO_27001_certificate_.png) ISO 27001 | ![9001:2015_Zertifikatssiegel](https://info.profil.com/hubfs/BLUE_MOON/piktos/ISO_9001-2015_certificate.png) ISO 9001:2015 ![9001:2015_Zertifikatssiegel](https://info.profil.com/hubfs/BLUE_MOON/piktos/BVMA_Logo_Certificate_size.png) BVMA Member | | --- | --- | ![blank.jpg](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Publications.png?width=44&height=49&name=Icon_Publications.png) #### Publications Marquard J. et al., 2015. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nature Medicine 21, 363–372 (2015). [View all](https://info.profil.com/knowledge-center/publications?hsLang=zh) ###### Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9 · 41460 - Neuss, Germany Telefon +49-2131-4018-345 · marketing@profil.com [Imprint](https://www.profil.com/imprint?hsLang=zh) | [Privacy Policy](https://www.profil.com/privacy?hsLang=zh)